Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company specializing in Gynaecology, Orthopaedics, and Dermatology. It operates primarily in India, holding competitive positions in these key therapeutic areas.
In FY26, the company experienced a 6% YoY revenue growth reaching ₹2,230 Mn, with an operational PAT increase of 12.5%. This demonstrates their continued profitability and resilience despite modest quarterly performance.
The accumulation of a cash balance of ₹1,757 Mn indicates robust free cash flow generation, underscoring their strong financial position and capacity for strategic investment or distribution to shareholders.
Jagsonpal focuses on maintaining strong brand equity. Its diversification into acquiring the Yash Pharma business has enhanced its portfolio, paving the path for further growth in attractive market segments.
Innovations in their product pipeline and adherence to market demands are supported by partnerships and strategic product launches, strengthening their competitive edge in the pharmaceutical sector.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,226 Cr
High Risk
30.2
32.0
0.7
4.9
301.80
154.90
Sales CAGR
Profit CAGR
ROE
ROCE
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockJagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is currently trading at 183.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company specializing in Gynaecology, Orthopaedics, and Dermatology. It operates primarily in India, holding competitive positions in these key therapeutic areas. In FY26, the company experienced a 6% YoY revenue growth reaching ₹2,230 Mn, with an operational PAT increase of 12.5%. This demonstrates their continued profitability and resilience despite modest quarterly performance. The accumulation of a cash balance of ₹1,757 Mn indicates robust free cash flow generation, underscoring their strong financial position and capacity for strategic investment or distribution to shareholders. Jagsonpal focuses on maintaining strong brand equity. Its diversification into acquiring the Yash Pharma business has enhanced its portfolio, paving the path for further growth in attractive market segments. Innovations in their product pipeline and adherence to market demands are supported by partnerships and strategic product launches, strengthening their competitive edge in the pharmaceutical sector.
Over the past 52 weeks, Jagsonpal Pharmaceuticals Ltd has traded between a low of ₹154.90 and a high of ₹301.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Jagsonpal Pharmaceuticals Ltd has a market capitalization of approximately 1,226.08. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Jagsonpal Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 30.19 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,226.08 Cr, Jagsonpal Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Jagsonpal Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Jagsonpal Pharmaceuticals Ltd is 30.19. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The board of Jagsonpal Pharmaceuticals has approved a buyback price of ₹250 per equity share through a tender offer.
The board of Jagsonpal Pharmaceuticals has approved a buyback of up to 16 lakh shares at a price of ₹250 per share, with a total maximum value of ₹40 crore. The buyback will be conducted through a tender offer.
Bearish
5
Neutral
5
Bullish
4
Bearish
17
Neutral
5
Bullish
24
Bearish
12
Neutral
0
Bullish
20
Tax Assessment
Jagsonpal Pharmaceuticals received an income-tax assessment order (s.143(3) read with s.144B) dated Mar 12, 2026 for AY 2024-25, raising a demand of Rs. 4,81,61,360 due to disallowance of expenses; the company will appeal and expects no material impact.
Buyback Announcement
Jagsonpal Pharmaceuticals approved a tender-offer buyback of up to 1.6 million shares at ₹250/share (total ₹40 crore), subject to shareholder approval; promoters will not participate, raising promoter stake from 67.2% to 68.9% if fully subscribed.
Buyback Offer
Jagsonpal Pharmaceuticals' board approved a proposal for a tender‑offer buyback of up to 16,00,000 equity shares at ₹250/share (max ₹40 crore; 2.39% of paid‑up capital), subject to shareholder and statutory approvals; promoters will not participate.
Buyback Announcement
Board approved proposal to buy back up to 16,00,000 equity shares (2.39% of paid-up capital) at Rs.250/share aggregating up to Rs.40 crore via a proportionate tender offer, subject to shareholder and statutory approvals; promoters will not participate.
Buyback Proposal
Jagsonpal Pharmaceuticals informed exchanges that its board will meet on March 12, 2026 to consider and approve a proposal to buy back fully paid equity shares (face value Rs.2) and related matters.
ESOP Grant
Nomination & Remuneration Committee approved grant of 1,152,500 employee stock options under the 2022 ESOP Plan at an exercise price of Rs.139 each; options convert to Rs.2 equity shares and vest in 4 equal annual tranches from Mar 2027.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
183.10 | 1,226 Cr | 30.19 | 4.85 | 1.35 | 17.30 | 21.58 | 13.68 | |
603.45 | 1,209 Cr | 13.76 | 1.69 | 0.30 | 11.18 | 15.34 | 10.28 | |
1385.00 | 1,199 Cr | 27.73 | 3.55 | 0.50 | 12.98 | 9.93 | 6.29 | |
894.05 | 1,195 Cr | 15.66 | 2.01 | 0.00 | 10.66 | 13.99 | 9.93 | |
518.75 | 1,154 Cr | 45.69 | 3.81 | 0.00 | 6.43 | 8.43 | 5.62 | |
12.12 | 1,136 Cr | 15.54 | 3.00 | 0.00 | 16.66 | 22.00 | 15.12 | |
1116.50 | 1,132 Cr | 26.57 | 4.96 | 0.00 | 18.96 | 18.07 | 0.00 | |
| Median: 7 Co. | 603.45 | 1,195 Cr | 26.57 | 3.55 | 0.00 | 12.98 | 15.34 | 9.93 |
